Alnylam Pharmaceuticals, Inc. (ALNY)
288.47
+1.49
(+0.52%)
USD |
NASDAQ |
May 18, 12:05
Alnylam Pharmaceuticals Research and Development Expense (Quarterly) : 364.87M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Aldeyra Therapeutics, Inc. | 2.410M |
| Ionis Pharmaceuticals, Inc. | 210.17M |
| Gilead Sciences, Inc. | 1.354B |
| Regeneron Pharmaceuticals, Inc. | 1.420B |
| Sarepta Therapeutics, Inc. | 153.96M |